The botanical raw material was shipped to Filament’s Vancouver facility for analysis and development into ibogaine extract VANCOUVER, BC, May 17, 2023 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced the completion of the first-ever Nagoya Protocol-compliant import of…

Source

Previous articleClearmind Medicine to Host Virtual Investor Conference on Psychedelics for Obesity
Next articleTerran Biosciences discovers what may be the first new salts, co-crystals, and polymorphs of psilocybin in history, publishes PCT patent application, and files psilocybin Drug Master File (DMF) with FDA